

1 **Title:**

2 Pregnancy outcomes, Newborn complications and Maternal-Fetal Transmission of SARS-CoV-2  
3 in women with COVID-19: A systematic review of 441 cases

4 **Authors:**

5 Rahul K GAJBHIYE, MBBS, PhD <sup>1</sup>,

6 Deepak N MODI, PhD <sup>2</sup>,

7 Smita D MAHALE, PhD <sup>3</sup>

8 **Author Affiliations:**

9 <sup>1</sup>Department of Clinical Research, <sup>2</sup>Molecular and Cellular Biology Laboratory, <sup>3</sup>Structural  
10 Biology Department, ICMR-National Institute for Research in Reproductive Health, J M Street,  
11 Parel, Mumbai, 400012, INDIA

12 **Corresponding Author:**

13 Rahul Gajbhiye, MBBS, PhD

14 Scientist D & DBT Wellcome India Alliance Clinical and Public Health Intermediate Fellow

15 Department of Clinical Research

16 ICMR- National Institute for Research in Reproductive Health,

17 J M Street, Parel, Mumbai 400012 INDIA

18 Telephone: +91 22 24192036

19 Email : [gajbhiyer@nirrh.res.in](mailto:gajbhiyer@nirrh.res.in)

20 **Disclosure statement:** All authors report no conflict of interest.

21

22

23

24 **ABSTRACT**

25 **Objective:** The aim of this systematic review was to examine the maternal and fetal outcomes  
26 in pregnant women with COVID-19 and also assess the incidence of maternal-fetal transmission  
27 of SARS CO-V-2 infection.

28 **Data sources:** We searched PUMBED, Medline, Embase, MedRxiv and bioRxiv databases upto  
29 3<sup>rd</sup> May 2020 utilizing combinations of word variants for “coronavirus” or “COVID-19” or  
30 “severe acute respiratory syndrome” or “SARS-COV-2” and “pregnancy”. We also included  
31 data from preprint articles.

32 **Study eligibility criteria :** Original case reports and case series on pregnant women with  
33 diagnosis of SARS-CoV-2 infection.

34 **Study appraisal and synthesis methods :** We included 50 studies reporting the information on  
35 441 pregnant women and 391 neonates. The primary outcome measures were maternal health  
36 characteristics and adverse pregnancy outcomes, neonatal outcomes and SARS-CoV-2 infection  
37 in neonates was extracted. Treatments given to pregnant women with COVID-19 were also  
38 recorded.

39 **Results:** Out of 441 women affected by COVID-19 in pregnancy, 387 women have delivered.  
40 There are nine maternal deaths reported. In pregnant women with COVID-19, the most common  
41 symptoms were fever (56%), cough (43%), myalgia (19%), dyspnea (18%) and diarrhea (6%).  
42 Pneumonia was diagnosed by CT scan imaging in 96 % of COVID-19 pregnant women.  
43 Pregnancy complications included delivery by cesarean section (80%), preterm labor (26%),  
44 fetal distress (8%) and premature rupture of membranes (9%). Six still births (2%) are reported.  
45 The most common co-morbidities associated with pregnant women with COVID-19 were  
46 hypertensive disorders (10%), diabetes (9%), placental disorders (2%), co-infections (3%),

47 scarred uterus (3%) and hypothyroidism (3%). Amongst the neonates of COVID-19 mothers,  
48 preterm birth (25%), respiratory distress syndrome (8%), pneumonia (8%) were reported. There  
49 were four neonatal deaths reported. Vertical transmission rate of SARS-CoV-2 is estimated to  
50 be 8%.

## 51 **Conclusion**

52 In pregnant women with COVID-19, hypertensive disorders and diabetes are common co-  
53 morbidities and there is a risk of preterm delivery and maternal death. Amongst the neonates  
54 born to mothers with COVID-19, respiratory distress syndrome and pneumonia are common  
55 occurrence. There are reports of still births and neonatal deaths. There is an evidence of vertical  
56 transmission of SARS-CoV-2 infection in women with COVID-19.

57

58 **Keywords:** Coronavirus, COVID-19, pregnancy, death, newborn, still birth, SARS-COV-2,  
59 vertical transmission, treatment

60

61 **INTRODUCTION**

62 Coronaviruses are known to infect humans, other mammals, and birds causing respiratory,  
63 enteric, hepatic, and neurologic diseases <sup>1</sup>. Amongst these is a novel corona virus SARS-CoV-2,  
64 first time reported from Wuhan in China in December 2019 and causes a potentially life-  
65 threatening respiratory disease termed as COVID-19 <sup>2</sup>. Since then, SARS-CoV-2 infection is  
66 reported from every country in the world has rapidly spread across the globe creating a massive  
67 public health problem. Owing to the high rates of human to human transmission, WHO declared  
68 COVID-19 as a pandemic <sup>3</sup>. More than 3.1 million confirmed cases of COVID-19 and almost  
69 2,24,172 reported deaths (upto 1st May, 2020), the pandemic has reportedly affected more than  
70 180 countries/regions globally and majority of them are in local transmission phase<sup>4</sup>. Since this  
71 virus has not been detected in humans before, limited information is available about its effect on  
72 people; almost negligible information is available in pregnant women. Previously, members of  
73 the coronavirus family such as (SARS-CoV) and Middle East respiratory syndrome (MERS-  
74 CoV) are reported to be associated with severe complications during pregnancy like miscarriage,  
75 fetal growth restriction, preterm birth and maternal deaths <sup>5</sup>. During the influenza pandemic in  
76 1918, there was a higher mortality (37%) among pregnant women as compared to mortality rate  
77 in the overall population (2.6%)<sup>6</sup>. During the SARS Co-V pandemic in 2003, 50% of pregnant  
78 women with SARS Co-V infection were admitted to the intensive care unit (ICU). Out of these,  
79 around 33% of pregnant required mechanical ventilation, with mortality rate of 25%<sup>7</sup>.

80

81 Pregnant women are particularly susceptible to respiratory pathogens and severe pneumonia,  
82 due to various factors such as physiologic changes in the immune and cardiopulmonary systems  
83 (e.g. elevation of the diaphragm, increased oxygen consumption, and edema of respiratory tract

84 mucosa), which make them at risk of hypoxia<sup>8</sup>. Furthermore, during the pandemic, hospital  
85 visits may enhance the chances of infection and conversely lack of medical care during  
86 pregnancy may do more harm. Hence, there is an urgent need to devise appropriate management  
87 protocols for pregnant women to access maternal health care with minimum exposure risk is  
88 desired during the current COVID-19 outbreak. However, this would require a thorough  
89 situational analysis of COVID-19 and pregnancy.

90

## 91 **OBJECTIVE**

92 The aim of this systematic review was to assess the maternal and neonatal outcomes in pregnant  
93 women with COVID-19. We also assessed if there is any evidence of the maternal-fetal  
94 transmission of SARS CO-V-2 infection. We believe this information will aid obstetricians and  
95 neonatologists to take evidence based decisions to manage pregnant women with COVID-19 and  
96 their newborns. This information will also help the societies of obstetricians and gynecologists to  
97 devise appropriate guidelines and management of pregnancy and coronavirus diseases in general.

98

## 99 **METHODS**

### 100 *Eligibility criteria, information sources, search strategy*

101 We performed a systematic search in PUBMED, Medline, Google Scholar, preprint servers  
102 medRxiv, bioRxiv and arXiv databases utilizing combinations of word variants for  
103 “coronavirus”, 2019 n-COV. or “COVID-19” and “pregnancy”. The time line was restricted until  
104 3<sup>rd</sup> May, 2020, no language restrictions were imposed (the articles were translated in English  
105 using google translator). We also applied snowballing method to identify any missed articles. For  
106 each search strategy, two authors (RG, DM) reviewed all the abstracts. Reviews, narrative

107 articles, abstracts, duplicates were excluded for analysis. One article in German language could  
108 not be translated and hence excluded. Special attention was paid to exclude grey literature like  
109 media reports, blogs and information from unverified sources. Since the publication of our  
110 preprint in April 2020<sup>9</sup>, two studies from China were published that described clinical  
111 characteristics and outcomes of 116 and 118 pregnant women with COVID-19<sup>10,11</sup>. The data in  
112 these studies were directly from hospital records<sup>10</sup> or from medical records extracted from  
113 National Health Commission of China<sup>11</sup>. We compared the information from our systematic  
114 search and those of the two studies and observed there was a considerable overlap in the patient  
115 population between the three datasets. Considering the risk of oversampling and the fact that our  
116 literature search captured information on more women from China (n=319), both these studies  
117 were excluded. The systematic review protocol was not registered due to the urgency of the  
118 matter and we did not anticipate much of evidence. Considering the nature of the studies and the  
119 outcome measures available, we could not adhere to all the guidelines of PRISMA. Although the  
120 Synthesis Without Meta-analysis (SWiM) reporting guidelines<sup>12</sup> were followed. No patients or  
121 public were involved in the study design, conduct or reporting of our analysis.

### 122 *Study selection*

123 The articles were shortlisted independently by DM and RG to include only the original studies  
124 reporting information on pregnant women with a diagnosis of SARS-CoV-2 infection (Fig.1).  
125 The primary outcome measures were maternal clinical presentation, co-morbidities, adverse  
126 pregnancy outcomes, neonatal outcomes and SARS-CoV-2 infection in neonates. Third author  
127 (SM) coordinated the discussion for agreement of the shortlisted articles and looked for  
128 inconsistencies by randomly selecting a subset of articles (20%). The data underwent two rounds  
129 of iterations and verifications until all the inconsistencies in the data entries by RG and DM were

130 sorted and all the authors agreed on the outcome measures. The inherent nature of the studies  
131 precluded us from ranking the quality of these studies.

### 132 *Data extraction*

133 Since most were case reports and case series, individual patient data was available from these  
134 studies and entered in the table format. In the event the primary outcomes were not reported in  
135 the studies, we assumed that these did not occur in the patients and were entered as absent. Data  
136 was not available for the all the primary outcomes in all the included studies. Thus, for each  
137 primary outcome, only studies where the information was available were included for  
138 calculations and further analysis. As a secondary outcome RG independently collected data on  
139 the treatments given to pregnant women with COVID-19. As the information is sparse, it could  
140 not be organized systematically for analysis and hence it is only included in a narrative manner  
141 in the present review.

## 142 **RESULTS**

### 143 *Study selection*

144 Overall, 1503 articles were identified through database searches and snowballing. After  
145 screening and assessment of eligibility (Fig. 1); 50 studies were found eligible for inclusion and  
146 analyzed in the systematic review (Supplementary table 1). These were mainly case series and  
147 case reports from China (n=30)<sup>10-39</sup>, USA (n=4)<sup>43-46</sup>, Iran (n=3)<sup>47-49</sup>, one each from Australia<sup>50</sup>,  
148 Canada<sup>51</sup>, Republic of Korea<sup>36</sup>, Honduras in Central America<sup>37</sup>, Jordan<sup>54</sup>, Spain<sup>55</sup>, Peru<sup>56</sup>,  
149 Sweden<sup>57</sup>, Turkey<sup>58</sup>, Italy<sup>59</sup>, Portugal<sup>60</sup>, Switzerland<sup>61</sup> and India<sup>62</sup>.

### 150 *Study characteristics*

151 In most of the studies, COVID-19 diagnosis in the pregnant women was confirmed by molecular  
152 detection of SARS-CoV-2 in at least the throat swabs. Cumulatively, the data on 441 pregnant

153 women (age range 20-49 years) was available; of which 387 have delivered which include 4 sets  
154 of twins, 4 induced abortions, 6 still births and remaining are ongoing pregnancies  
155 (Supplementary table 1). Three hundred and nineteen of the 441 pregnant women with COVID-  
156 19 are from China and the rest (n= 122) were from other parts of the world. Ninety-five percent  
157 of the women were in the 3<sup>rd</sup> trimester of pregnancy and 5% of women had gestational age less  
158 than 28 weeks. Almost 50% of cases, there was a history of the women residing either in the  
159 epicenter of COVID-19 epidemic or they were in direct contact with COVID-19 confirmed  
160 cases. In the remaining women the source of infection is unknown and is possibly via a  
161 community transmission. Amongst the pregnant women with COVID-19, 80% underwent  
162 cesarean section and the rest had vaginal delivery (Supplementary table 1). The reason for  
163 cesarean section was either fetal distress or was an empirical decision made by the obstetricians  
164 in consultation with the patients. In the reported studies, cesarean sections were reported to be  
165 conducted in a negative-pressure isolation room by skillful medical team with enhanced personal  
166 protective equipments (PPEs) including N95 masks, surgical cap, double gown, double gloves,  
167 shoe covers, and powered air-purifying respirator for safe delivery.

### 168 ***Maternal complications in COVID-19***

169 The detailed breakup of the individual studies reporting maternal presentations and outcomes are  
170 given in Supplementary table 2 and the data is represented in Fig 2. The most common  
171 symptoms were fever (56%), cough (43%) and myalgia (19%). In a proportion of women  
172 dyspnea (18%) has also been reported. The major co-morbidities (Fig 2, Supplementary table 3)  
173 reported in women with COVID-19 were hypertensive disorders (10%) which included  
174 preeclampsia, gestational and chronic hypertension; diabetes (9%) including gestational diabetes,  
175 Type 1 and Type 2 Diabetes Mellitus (DM). The other co-morbidities were placental



176 abnormalities (2%), co-infections (3%), scarred uterus (3%) and hypothyroidism (3%).  
177 Umbilical cord abnormalities were also reported in 2 cases. Placental abnormalities included  
178 placenta previa, placenta accreta and abruptio placenta. The adverse pregnancy outcomes (Fig. 2)  
179 included preterm labor (26%), fetal distress (8%), premature rupture of membranes [PROM  
180 (9%)].  
181 Serious morbidities were reported in 11% of pregnant women with COVID-19 as they required  
182 ICU care with mechanical ventilation; of these, 10 women developed multi-organ dysfunction  
183 and were kept on extracorporeal membrane oxygenation (ECMO). Twenty four percent of  
184 women required oxygen support with nasal cannula. Due to paucity of time, we could not contact  
185 the authors of the original study to know the status of the patient kept on ECMO. Nine maternal  
186 deaths are reported amongst the studies included.

### 187 *Complications in infants born to COVID-19 mothers*

188 Of the 391 neonates born to COVID-19 mothers, (Supplementary Table 4); neonatal data was  
189 not available from all the pregnant women with COVID-19, conversely not all maternal  
190 information was available in studies reporting neonatal outcomes of COVID-19 mothers. Thus,  
191 the data in Supplementary table 1 and Supplementary table 4 may not completely overlap.  
192 Table 1 gives the details of the neonatal data available from these studies. In all there were 78  
193 male and 47 female neonates (ratio 1.6) born to COVID-19 mothers. Preterm birth was reported  
194 in 25% of the neonates and Respiratory Distress Syndrome in 8%. There were six still births and  
195 four neonatal deaths reported. A proportion of neonates were admitted to the neonatal intensive  
196 care unit (NICU) with serious complications such as pneumonia (8%). Three hundred and  
197 thirteen neonates were tested for SARS-CoV-2 infections by RT-PCR and or antibody assay. In  
198 remaining neonates, the reasons for not testing were lack of reagents, non-willingness of parents

199 and refusal to consent. SARS-CoV-2 infection was reported in 24/313 (8%) of neonates born to  
200 mothers with COVID-19. Of these , 7% were positive by RT-PCR and 3% by antibody testing  
201 method.

### 202 ***Mother to child transmission of COVID-19***

203 To address the extent of maternal to fetal transmission of SARS-CoV-2, we carried out a  
204 subgroup analysis where we compiled the data from the publications that explicitly reported the  
205 neonatal SARS-CoV-2 testing by the type of laboratory method used (RT-PCR or antibody or  
206 both), the neonatal samples tested and the time of testing. We further employed a strict criterion  
207 to select the studies where the diagnosis was confirmed by RT-PCR or by presence of IgM  
208 antibodies only within the first 48h of life and where the source of sampling was clearly  
209 mentioned. Table 2 gives the details of the SARS-CoV-2 infected neonates reported in the  
210 studies. In all, 261/313 neonates (84%) met the above criteria and of these, 21 tested positive for  
211 SARS-CoV-2 resulting in a possible vertical transmission rate of 8% (Supplementary Table 5).  
212 In one case amniotic fluid and in once case placenta and fetal membrane was also found to be  
213 positive for SARS-CoV-2 by RT-PCR.

### 214 ***Treatment and management of SARS-CoV-2 in pregnant women***

215 Table 3 gives the treatments given to the pregnant women with COVID-19. Amongst the studies  
216 selected, 327 women were reported to receive some form of treatment for COVID-19. In the  
217 described cases and case series, most women received individual and/or combinations of several  
218 antiviral drugs (63%) and antibiotics (55%) along with the steroids mainly methylprednisolone  
219 (11%). Seven studies reported use of Hydroxychloroquine (23% of women) and four studies  
220 reported use of traditional Chinese medicine (22% of women). However, the dosages, routes of  
221 administration, duration and timings of the treatment were not detailed in most of these studies.

222 **COMMENT**

223 In this large systematic review of 441 pregnant women with COVID-19 from 16 countries, we  
224 report a maternal death rate of 3%, still births (1.6%) and neonatal death rate of 1%.  
225 Hypertensive disorders and diabetes are common co-morbidities; 26% of these women delivered  
226 preterm with fetal distress and PROM being other pregnancy related complications. The adverse  
227 neonatal outcomes associated with pregnant women with COVID-19 include neonatal respiratory  
228 distress, and pneumonia. Almost these 8% of babies are born to mothers with COVID-19 had  
229 SARS-CoV-2 infection.

230 Previous systematic reviews and large case series on pregnant women with COVID-19 are  
231 mainly from China<sup>10,11,63-65</sup>. The present systematic review is generated from 50 case series and  
232 case reports from 16 countries of resulting in analysis 441 pregnant women with COVID-19. To  
233 our knowledge, this is the largest systematic review available to date generating evidence on  
234 pregnancy outcomes, complications and vertical transmission in women with COVID-19.  
235 Irrespective of the country, the clinical manifestations of COVID-19 in pregnant women were  
236 heterogeneous. Amongst the pregnant women who were SARS-CoV-2 positive, 56% presented  
237 with fever while 43% had cough. This numbers are lower than that in Chinese population which  
238 reported cough and fever in nearly 70% of pregnant women with COVID-19<sup>11</sup>. This observation  
239 implies that the clinical presentation of the women with SARS-CoV-2 may vary significantly in  
240 in different populations. In this regards, it is important to note that many women had mild  
241 disease and nearly 50% of the pregnant women were asymptomatic on initial presentation and  
242 were diagnosed with COVID-19 after admission for induction of labor. This was not only  
243 observed in Chinese population but also reported in women in other countries.<sup>32</sup>

244 These results imply that asymptomatic presentations are common in pregnant women and

245 represent a substantial risk of spreading the SARS-CoV-2 infection in the community. Given the  
246 numbers of exposed women, this is not unexpected and obstetricians must bear in mind that  
247 during the pandemic, hospitals must be prepared to deal with such atypical situations. However;  
248 the situation is alarming as it will increase the risk of exposure and infection to healthcare  
249 providers attending these women. There was an evidence of risk to the healthcare providers and  
250 four cases reported in this systematic review were physicians who acquired SARS-CoV-2  
251 infection while providing clinical services to the COVID-19 patients<sup>26,29</sup>.

252 Our observation highlights the need of appropriate precautions and use of protective measures  
253 especially use of personal protective equipments (PPEs) to reduce the risk of COVID-19 to the  
254 healthcare providers in obstetrics care. Our study also highlights the need of the universal  
255 screening strategy in obstetric population as many women do not present with classical  
256 symptoms or are even asymptomatic. Indeed, a recent study has shown that nearly 13% of  
257 women were afebrile but were SARS-CoV-2 positive when admitted for delivery<sup>66</sup>.

258 In this systematic review; hypertensive disorders, diabetes, and placental disorders were the top  
259 three co-morbidities identified in pregnant women with COVID-19. A nationwide study of 1590  
260 patients with COVID-19 in China reported hypertension (16.9%) and diabetes (8.2%) as the  
261 commonest co-morbidities and risk factor for poor outcomes in COVID-19<sup>34</sup>. Beyond these, co-  
262 infections, scarred uterus, and hypothyroidism were other co-morbidities observed in the group  
263 of pregnant women with COVID-19. Currently, there is no evidence whether thyroid disease is  
264 associated with increased risk of viral infections in general and specifically COVID-19 nor is  
265 there an association between thyroid disease and severity of the viral infection.

266

267 The adverse pregnancy outcomes reported in COVID-19 women were preterm labor, fetal  
268 distress and premature rupture of membranes. For preterm births, China reports an incidence of  
269 7.3 per 100 births or 6.7 per 100 live births<sup>36</sup>. However, the numbers of preterm birth observed in  
270 women with COVID-19 is comparatively higher (26%). Whether, preterm birth is a secondary  
271 complication of respiratory distress or induced directly due to viral infection needs to be  
272 determined.

273 Beyond preterm births, post-partum a substantial number of women required oxygen support,  
274 mechanical ventilation and ICU care. Treatment with extracorporeal membrane oxygenation  
275 (ECMO) was reported in some of the cases who became critically ill<sup>23,46</sup>. ECMO has been  
276 utilized in pregnancy to support oxygenation for H1N1 influenza and refractory ARDS<sup>69</sup> and it is  
277 considered as an alternative rescue strategy for COVID-19<sup>46</sup>. Thus, post-partum women with  
278 COVID-19 are also at a risk of developing serious complications warranting emergency  
279 preparedness by obstetricians, anesthetist and pulmonologists. Therefore, it is essential that  
280 proper triage of patients should be implemented by carefully documenting prior medical and  
281 surgical history to help identifying a subset of patients who are at risk of developing serious  
282 adverse outcomes of COVID-19.

283 Maternal deaths due to infection are a matter of concern. The mortality rate of SARS-CoV-2  
284 infection outside china is reported to be 1.5% and 3.6% in China<sup>38</sup>. Although, there are no  
285 maternal death reported in studies from China; nine maternal deaths related to COVID-19 are  
286 reported from Iran<sup>47,48</sup>. The authors are aware of two maternal deaths associated with COVID-19  
287 in India (unpublished information). It must be highlighted herein that most of the studies  
288 reported from China and elsewhere are women infected in the late third trimester or near term,  
289 the two maternal deaths reported from Iran were infected in late second trimester/early third

290 trimester (28-30 weeks). It appears that COVID-19 in late second trimester or earlier third  
291 trimester could be more detrimental to the pregnancy. However, more data from other parts of  
292 the world on pregnant women with COVID-19 is required to get an estimate of maternal  
293 mortality in this condition.

294

295 Viral infections during pregnancy such as influenza A are reported to be associated with adverse  
296 neonatal outcomes and increased the risk of low birth weight babies<sup>40</sup>. Similar observation was  
297 found in pregnancy with COVID-19. Low birth weight was reported in 8% of neonates born to  
298 mothers with COVID-19 (data not shown). LBW is a risk factor for later life disease  
299 susceptibility leading to chronic morbidity. Other common neonatal complications reported are  
300 respiratory distress and pneumonia; spontaneous abortions, still births and neonatal deaths are  
301 infrequently associated with corona virus infection in general. However, there were six still  
302 births and four neonatal deaths reported. This data suggests a substantial adverse impact of  
303 maternal COVID-19 on newborns. These observations strongly suggest the requirement of  
304 special care to be given to the newborns of mothers with COVID-19.

305 In all, the present study estimates that 8% of the neonates born to mothers with COVID-19 have  
306 SARS-CoV-2 infection. Initial studies reported that SARS-CoV-2 was not detected in placenta,  
307 amniotic fluid, cord blood, and neonatal throat swab samples<sup>42, 24, 25, 44</sup>. However, in a case  
308 series of 33 neonates born to COVID-19 women; 3 neonates were found to be positive for  
309 SARS-CoV-2 by RT-PCR<sup>13</sup>. Tests for IgG and IgM antibodies for SARS-CoV-2 became  
310 available in February 2020 and Dong et al.,<sup>14</sup> reported a newborn with elevated IgM antibodies  
311 to SARS-CoV-2 born to a mother with COVID-19. Zeng et al.,<sup>30</sup> reported IgG antibodies in 5  
312 infants and IgM antibodies in 2 infants. However, these infants were negative for SARS-CoV-2

313 upon molecular testing. While the reasons for such discrepancy could be multiple, a cause of  
314 concern could be the possible false negative diagnosis by RT-PCR. It is possible that in the IgM-  
315 positive RT-PCR-negative infants the viral load may be low and beyond the sensitivity of the  
316 existing RT-PCR methods. In this context, we must highlight that 7% of neonates (even those  
317 negative for SARS-CoV-2 by RT-PCR) developed pneumonia within first two days of life. This  
318 proportion is higher than the incidence of neonatal pneumonia in general population indicating  
319 the possibility of infection by the virus and perhaps the RT-PCR has more false negatives.  
320 Therefore, further studies should include rigorous clinical assessment of the newborn along with  
321 IgM testing or employ more sensitive methods in newborn samples to determine the burden of  
322 neonatal SARS-CoV-2.

323  
324 The present study aimed to answer an important question that whether SARS-CoV-2 can be  
325 transmitted from a pregnant mother to her fetus. This is more relevant based on the evidence of  
326 vertical maternal-fetal transmission of recent emerging viral infections including Zika virus,  
327 Ebola virus, Marburg virus which led to high maternal and infant mortality<sup>46</sup>. Whether, SARS-  
328 CoV-2 infection in the neonates was derived maternally or acquired ex utero is difficult to assess  
329 from these studies. However, we addressed this problem by applying strict criteria to include  
330 only those studies that clearly reported carrying out the diagnosis in the first 48h of life either by  
331 RT-PCR or by IgM antibodies against SARS-CoV-2. As IgM antibodies are not transferred to  
332 the fetus via the placenta<sup>48</sup>, the neonates even if RT-PCR negative but positive for IgM in first  
333 48h of life are presumed to acquire the infection in utero. The analysis revealed the possibility of  
334 intrauterine mother to child transmission, of SARS-CoV-2 in 8% of cases. The best practical  
335 approach to confirm the virus in placenta, amniotic fluid, cord blood and neonatal pharyngeal

336 swab samples<sup>69</sup>. In one instance SARS-CoV-2 virus was detected in the amniotic fluid by RT-  
337 PCR<sup>46</sup> one study reported viral mRNA in placental cotyledons and fetal membrane<sup>61</sup>. It is  
338 important to point out that in all these positive cases, the studies reported use of precautions like  
339 delivery in negative pressure rooms, wearing of N95 masks by mother and PPE by health care  
340 providers, and isolation of neonate immediately after delivery making an external acquisition  
341 unlikely. While more data is awaited, in this direction; we must consider that there is a  
342 reasonable possibility of mother to child transmission of SARS-CoV-2 and this may have long-  
343 term implications to fetal health. Policies must be devised keeping this gap in mind towards  
344 management of COVID-19 mothers and infants.

345  
346 At present, no specific treatments are available for COVID-19 and patients are symptomatically  
347 managed. In the reported studies, authors have mentioned administration of antivirals,  
348 antibiotics, steroids. Some studies reported use of Hydroxychloroquine and some with  
349 traditional Chinese medicine in the COVID-19 pregnant women. Some of the cases included the  
350 systematic review reported incidences of thrombotic complications. Considering the  
351 hypercoagulable state of pregnancy, high-prophylactic and therapeutic dosing of anticoagulation  
352 was given in critically ill patients<sup>49</sup>. However, the doses administered, the time and route of  
353 administration and the length of treatment are not specified in most studies. In absence of a well  
354 reported data, it is hard to draw any conclusions on what could be the effective therapies for  
355 COVID-19 in pregnancy.

356 As COVID-19 still appears to be spreading exponentially, the number of pregnant women with  
357 COVID-19 are likely to increase in different regions, countries, and continents. Therefore, at this  
358 time, it is important that all the stakeholders including pregnant women, their families, general



359 public and healthcare providers, receive as updated, accurate and authentic information regularly.

360 We believe that this systematic review will act as a primer for future studies and development of  
361 protocols for management of COVID-19 in pregnancy.

362

### 363 *Study limitations*

364 We could not contact the authors of the original studies to find out the status of women admitted  
365 in ICU and neonates in NICU so the maternal death and neonatal death data cannot be  
366 considered updated. As there were inconsistencies observed in some reports between the results  
367 and discussion sections, we feel that there is an element of bias in the reported studies and  
368 possibility of under-reporting of the symptoms by the authors. This may influence the  
369 proportions of morbidity reported herein. Considering the nature of the studies and the urgency  
370 of the situation, we could not strictly adhere to all the criteria for PRISMA and carry out a meta-  
371 analysis.

372

### 373 *Conclusions*

374 There is substantial risk of adverse pregnancy and neonatal outcomes in pregnant women with  
375 COVID-19. Evidence is garnered on preterm birth as commonest adverse neonatal outcomes;  
376 hypertensive disorders and GDM/DM and as co-morbid conditions in pregnant women with  
377 SARS-CoV-2 infection. There is an evidence of vertical transmission of SARS-CoV-2 infection  
378 in women with COVID-19. The study highlights an urgent need to bring together a  
379 multidisciplinary expertise comprising of maternal–fetal medicine and other experts globally  
380 with special emphasis on low and middle income countries to formulate evidence based clinical  
381 management guidelines for COVID-19 in pregnancy.

382

383 **Acknowledgements**

384 RG, DM and SM labs are funded by grants from Indian Council of Medical Research (ICMR).  
385 RG is an awardee of the DBT Wellcome India alliance clinical and public health intermediate  
386 fellowship (Grant no. IA/CPHI/18/1/503933). The manuscript bears ICMR-NIRRH ID  
387 RA/896/04-2020.

388 **Author Contributions:**

389 RG conceived the study. RG and DM designed the study. RG and DM screened the abstracts for  
390 inclusion in the study, extracted and analyzed the data. SM coordinated the discussion for  
391 agreement regarding potential relevance or inconsistencies and helped in data interpretation. RG  
392 and DM drafted the manuscript, which was critically revised by all authors. All authors approved  
393 the final manuscript.

394 **Funding:**

395 No specific funding was received for this study.

396 **Ethical Approval:** Not required

397

## 398 References:

- 399 1. Weiss SR, Leibowitz JL. Chapter 4 - Coronavirus Pathogenesis. In: Maramorosch K, Shatkin AJ,  
400 Murphy FA, eds. *Advances in Virus Research*. Vol 81. Academic Press; 2011:85-164.  
401 doi:10.1016/B978-0-12-385885-6.00009-2
- 402 2. Naming the coronavirus disease (COVID-19) and the virus that causes it. Accessed April 6, 2020.  
403 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)  
404 [the-coronavirus-disease-\(covid-2019\)-and-the-virus-that-causes-it](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it)
- 405 3. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020.  
406 Accessed April 6, 2020. [https://www.who.int/dg/speeches/detail/who-director-general-s-opening-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)  
407 [remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020)
- 408 4. COVID-19 situation reports. Accessed May 2, 2020.  
409 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- 410 5. Alfaraj SH, Al-Tawfiq JA, Memish ZA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV)  
411 infection during pregnancy: Report of two cases & review of the literature. *J Microbiol Immunol*  
412 *Infect.* 2019;52(3):501-503. doi:10.1016/j.jmii.2018.04.005
- 413 6. Gottfredsson M. [The Spanish flu in Iceland 1918. Lessons in medicine and history]. *Laeknabladid.*  
414 2008;94(11):737-745.
- 415 7. Schwartz DA. An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and  
416 Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy  
417 Outcomes. *Arch Pathol Lab Med*. Published online March 17, 2020. doi:10.5858/arpa.2020-0901-  
418 SA
- 419 8. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report based  
420 on 116 cases. *Am J Obstet Gynecol.* 2020;0(0). doi:10.1016/j.ajog.2020.04.014
- 421 9. Gajbhiye R, Modi D, Mahale S. Pregnancy outcomes, Newborn complications and Maternal-Fetal  
422 Transmission of SARS-CoV-2 in women with COVID-19: A systematic review. *medRxiv*. Published  
423 online January 1, 2020:2020.04.11.20062356. doi:10.1101/2020.04.11.20062356
- 424 10. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report based  
425 on 116 cases. *Am J Obstet Gynecol.* 2020;0(0). doi:10.1016/j.ajog.2020.04.014
- 426 11. Chen L, Li Q, Zheng D, et al. Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan,  
427 China. *N Engl J Med.* 2020;0(0):null. doi:10.1056/NEJMc2009226
- 428 12. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic  
429 reviews: reporting guideline. *BMJ.* 2020;368. doi:10.1136/bmj.l6890
- 430 13. Zeng L, Xia S, Yuan W, et al. Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born  
431 to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr.* Published online March 26, 2020.  
432 doi:10.1001/jamapediatrics.2020.0878

- 433 14. Dong L, Tian J, He S, et al. Possible Vertical Transmission of SARS-CoV-2 From an Infected Mother  
434 to Her Newborn. *JAMA*. Published online March 26, 2020. doi:10.1001/jama.2020.4621
- 435 15. Liu D, Li L, Wu X, et al. Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease  
436 (COVID-19) Pneumonia: A Preliminary Analysis. *AJR Am J Roentgenol*. Published online 2020:1-6.  
437 doi:10.2214/AJR.20.23072
- 438 16. Li Y, Zhao R, Zheng S, et al. Lack of Vertical Transmission of Severe Acute Respiratory Syndrome  
439 Coronavirus 2, China. *Emerg Infect Dis*. 2020;26(6). doi:10.3201/eid2606.200287
- 440 17. Liu W, Wang Q, Zhang Q, et al. Coronavirus Disease 2019 (COVID-19) During Pregnancy: A Case  
441 Series. Published online February 25, 2020. Accessed April 4, 2020.  
442 <https://www.preprints.org/manuscript/202002.0373/v1>
- 443 18. Zhu H, Wang L, Fang C, et al. Clinical analysis of 10 neonates born to mothers with 2019-nCoV  
444 pneumonia. *Transl Pediatr*. 2020;9(1):51-60. doi:10.21037/tp.2020.02.06
- 445 19. Zhang L, Jiang Y, Wei M, et al. Analysis of the pregnancy outcomes in pregnant women with  
446 COVID-19 in Hubei Province. *Zhonghua Fu Chan Ke Za Zhi*. 2020;55(0):E009-E009.  
447 doi:10.3760/cma.j.cn112141-20200218-00111
- 448 20. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission  
449 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical  
450 records. *The Lancet*. Published online 2020. doi:10.1016/S0140-6736(20)30360-3
- 451 21. Yu N, Li W, Kang Q, et al. Clinical features and obstetric and neonatal outcomes of pregnant  
452 patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet*  
453 *Infect Dis*. 2020;0(0). doi:10.1016/S1473-3099(20)30176-6
- 454 22. Chen S, Liao E, Shao Y. Clinical analysis of pregnant women with 2019 novel coronavirus  
455 pneumonia. *J Med Virol*. 2020;n/a(n/a). doi:10.1002/jmv.25789
- 456 23. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during  
457 pregnancy. *J Infect*. Published online March 4, 2020. doi:10.1016/j.jinf.2020.02.028
- 458 24. Chen S, Huang B, Luo DJ, et al. Pregnant women with new coronavirus infection: a clinical  
459 characteristics and placental pathological analysis of three cases. *Zhonghua Bing Li Xue Za Zhi*.  
460 2020;49(0):E005-E005. doi:10.3760/cma.j.cn112151-20200225-00138
- 461 25. Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). *Front*  
462 *Pediatr*. 2020;8. doi:10.3389/fped.2020.00104
- 463 26. Fan C, Lei D, Fang C, et al. Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We  
464 Worry? *Clin Infect Dis Off Publ Infect Dis Soc Am*. Published online 2020. doi:10.1093/cid/ciaa226
- 465 27. Wang X, Zhou Z, Zhang J, Zhu F, Tang Y, Shen X. A case of 2019 Novel Coronavirus in a pregnant  
466 woman with preterm delivery. *Clin Infect Dis*. Published online 2020:ciaa200.  
467 doi:10.1093/cid/ciaa200

- 468 28. Wang S, Guo L, Chen L, et al. A Case Report of Neonatal 2019 Coronavirus Disease in China. *Clin*  
469 *Infect Dis*. doi:10.1093/cid/ciaa225
- 470 29. Chen R, Zhang Y, Huang L, Cheng B-H, Xia Z-Y, Meng Q-T. Safety and efficacy of different anesthetic  
471 regimens for parturients with COVID-19 undergoing Cesarean delivery: a case series of 17 patients  
472 TT - Securite et efficacite de differents modes danesthesie pour des parturientes infectees par la  
473 COVID-19 accouchant par cesarienne: une serie de 17cas. *Can J Anaesth J Can Anesth*. Published  
474 online 2020. doi:10.1007/s12630-020-01630-7
- 475 30. Zeng H, Xu C, Fan J, et al. Antibodies in Infants Born to Mothers With COVID-19 Pneumonia. *JAMA*.  
476 Published online March 26, 2020. doi:10.1001/jama.2020.4861
- 477 31. Liao X, Yang H, Kong J, Yang H. Chest CT Findings in a Pregnant Patient with 2019 Novel  
478 Coronavirus Disease. *Balk Med J*. Published online March 26, 2020.  
479 doi:10.4274/balkanmedj.galenos.2020.2020.3.89
- 480 32. Li N, Han L, Peng M, et al. Maternal and neonatal outcomes of pregnant women with COVID-19  
481 pneumonia: a case-control study. *medRxiv*. Published online January 1,  
482 2020:2020.03.10.20033605. doi:10.1101/2020.03.10.20033605
- 483 33. Khan S, Peng L, Siddique R, et al. Impact of COVID-19 infection on pregnancy outcomes and the risk  
484 of maternal-to-neonatal intrapartum transmission of COVID-19 during natural birth. *Infect Control*  
485 *Hosp Epidemiol*. Published online 2020:1-3. doi:10.1017/ice.2020.84
- 486 34. Khan S, Jun L, Nawsherwan, et al. Association of COVID-19 infection with pregnancy outcomes in  
487 healthcare workers and general women. *Clin Microbiol Infect*. Published online April 8, 2020.  
488 doi:10.1016/j.cmi.2020.03.034
- 489 35. Liu F, Liu H, Li J, Hou L, Lan W, Wang D. *Clinico-Radiological Features and Outcomes in Pregnant*  
490 *Women with COVID-19: Compared with Age-Matched Non-Pregnant Women*. Social Science  
491 Research Network; 2020. doi:10.2139/ssrn.3556647
- 492 36. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers  
493 with COVID-19. *Front Med*. Published online April 13, 2020:1-6. doi:10.1007/s11684-020-0772-y
- 494 37. Nie R, Wang S, Yang Q, et al. Clinical features and the maternal and neonatal outcomes of  
495 pregnant women with coronavirus disease 2019. *medRxiv*. Published online January 1,  
496 2020:2020.03.22.20041061. doi:10.1101/2020.03.22.20041061
- 497 38. Wu C, Yang W, Wu X, et al. Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2  
498 Infection in Pregnant Women. *Virolog Sin*. Published online April 20, 2020. doi:10.1007/s12250-020-  
499 00227-0
- 500 39. Wu X, Sun R, Chen J, Xie Y, Zhang S, Wang X. Radiological findings and clinical characteristics of  
501 pregnant women with COVID-19 pneumonia. *International Journal of Gynecology & Obstetrics*.  
502 Published April 8, 2020. Accessed May 2, 2020.  
503 <https://obgyn.onlinelibrary.wiley.com/doi/abs/10.1002/ijgo.13165>

- 504 40. Lu Zhang, Lan Dong, Lei Ming, et al. Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-  
505 2) infection during late pregnancy: A Report of 18 patients from Wuhan, China. *Prepr Version 2*  
506 *Available Res Sq Httpsdoiorg1021203rs3rs-18247v2*.
- 507 41. Yang P, Wang X, Liu P, et al. Clinical characteristics and risk assessment of newborns born to  
508 mothers with COVID-19. *J Clin Virol*. 2020;127:104356. doi:10.1016/j.jcv.2020.104356
- 509 42. Hu X, Gao J, Luo X, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical  
510 Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia.  
511 *Obstet Gynecol*. 2020;Publish Ahead of Print. doi:10.1097/AOG.0000000000003926
- 512 43. Breslin N, Baptiste C, Miller R, et al. COVID-19 in pregnancy: early lessons. *Am J Obstet Gynecol*  
513 *MFM*. Published online March 27, 2020:100111. doi:10.1016/j.ajogmf.2020.100111
- 514 44. Breslin N, Baptiste C, Gyamfi-Bannerman C, et al. Coronavirus disease 2019 infection among  
515 asymptomatic and symptomatic pregnant women: two weeks of confirmed presentations to an  
516 affiliated pair of New York City hospitals. *Am J Obstet Gynecol Mfm*. Published online April 9, 2020.  
517 doi:10.1016/j.ajogmf.2020.100118
- 518 45. Iqbal SN, Overcash R, Mokhtari N, et al. An Uncomplicated Delivery in a Patient with Covid-19 in  
519 the United States. *N Engl J Med*. 2020;382(16):e34. doi:10.1056/NEJMc2007605
- 520 46. Hirshberg A, Kern-Goldberger AR, Levine LD, et al. Care of critically ill pregnant patients with  
521 COVID-19: a case series. *Am J Obstet Gynecol*. Published online May 2020:S0002937820305159.  
522 doi:10.1016/j.ajog.2020.04.029
- 523 47. Karami P, Naghavi M, Feyzi A, et al. Mortality of a pregnant patient diagnosed with COVID-19: A  
524 case report with clinical, radiological, and histopathological findings. *Travel Med Infect Dis*.  
525 Published online April 11, 2020:101665. doi:10.1016/j.tmaid.2020.101665
- 526 48. Zamaniyan M, Ebadi A, Aghajanpoor Mir S, Rahmani Z, Haghshenas M, Azizi S. Preterm delivery in  
527 pregnant woman with critical COVID-19 pneumonia and vertical transmission. *Prenat Diagn*.  
528 2020;n/a(n/a). doi:10.1002/pd.5713
- 529 49. Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal Death Due to COVID-19 Disease. *Am*  
530 *J Obstet Gynecol*. Published online April 2020:S0002937820305160.  
531 doi:10.1016/j.ajog.2020.04.030
- 532 50. Lowe B, Bopp B. COVID-19 vaginal delivery – a case report. *Aust N Z J Obstet Gynaecol*. n/a(n/a).  
533 doi:10.1111/ajo.13173
- 534 51. Koumoutsea EV, Vivanti AJ, Shehata N, et al. COVID19 and acute coagulopathy in pregnancy. *J*  
535 *Thromb Haemost*. n/a(n/a). doi:10.1111/jth.14856
- 536 52. Lee KS. Pneumonia Associated with 2019 Novel Coronavirus: Can Computed Tomographic Findings  
537 Help Predict the Prognosis of the Disease? *Korean J Radiol*. Published online  
538 2020:10.3348/kjr.2020.0096. doi:10.3348/kjr.2020.0096

- 539 53. Zambrano LI, Fuentes-Barahona IC, Bejarano-Torres DA, et al. A pregnant woman with COVID-19 in  
540 Central America. *Travel Med Infect Dis*. Published online March 25, 2020:101639.  
541 doi:10.1016/j.tmaid.2020.101639
- 542 54. The first Jordanian newborn delivered to COVID-19 infected mother with no evidence of vertical  
543 transmission: A case report. Published online April 14, 2020. doi:10.21203/rs.3.rs-22938/v1
- 544 55. Alonso Díaz C, López Maestro M, Moral Pumarega MT, Flores Antón B, Pallás Alonso CR. Primer  
545 caso de infección neonatal por SARS-CoV-2 en España. *An Pediatría*. 2020;92(4):237-238.  
546 doi:10.1016/j.anpedi.2020.03.002
- 547 56. Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, Rosa ML. Severe COVID-19 during  
548 Pregnancy and Possible Vertical Transmission. *Am J Perinatol*. Published online April 18, 2020.  
549 doi:10.1055/s-0040-1710050
- 550 57. Gidlöf S, Savchenko J, Brune T, Josefsson H. COVID-19 in pregnancy with comorbidities: More  
551 liberal testing strategy is needed. *Acta Obstet Gynecol Scand*. 2020;n/a(n/a).  
552 doi:10.1111/aogs.13862
- 553 58. Kalafat E, Yaprak E, Cinar G, et al. Lung ultrasound and computed tomographic findings in pregnant  
554 woman with COVID-19. *Ultrasound Obstet Gynecol*. 2020;n/a(n/a). doi:10.1002/uog.22034
- 555 59. Ferrazzi E, Frigerio L, Savasi V, et al. Vaginal delivery in SARS-CoV-2 infected pregnant women in  
556 Northern Italy: a retrospective analysis. *BJOG Int J Obstet Gynaecol*. 2020;n/a(n/a).  
557 doi:10.1111/1471-0528.16278
- 558 60. Lyra J, Valente R, Rosário M, Guimarães M. Cesarean Section in a Pregnant Woman with COVID-19:  
559 First Case in Portugal. *Acta Médica Port Vol 33 No 13 2020 Ahead Print 33*. Published online 2020.  
560 doi:10.20344/amp.13883
- 561 61. Baud D, Greub G, Favre G, et al. Second-Trimester Miscarriage in a Pregnant Woman With SARS-  
562 CoV-2 Infection. *JAMA*. Published online April 30, 2020. doi:10.1001/jama.2020.7233
- 563 62. Sharma KA, Kumari R, Kachhawa G, et al. Management of the first patient with confirmed COVID-  
564 19 in pregnancy in India: From guidelines to frontlines. *Int J Gynecol Obstet*. 2020;n/a(n/a).  
565 doi:10.1002/ijgo.13179
- 566 63. Elshafeey F, Magdi R, Hindi N, et al. A systematic scoping review of COVID-19 during pregnancy  
567 and childbirth. *Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet*. Published online April 24,  
568 2020. doi:10.1002/ijgo.13182
- 569 64. Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. COVID19 during pregnancy: a systematic review of  
570 reported cases. *Am J Obstet Gynecol*. Published online April 17, 2020.  
571 doi:10.1016/j.ajog.2020.04.013
- 572 65. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of  
573 108 pregnancies. *Acta Obstet Gynecol Scand*. n/a(n/a). doi:10.1111/aogs.13867

- 574 66. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal Screening for SARS-CoV-2 in Women Admitted  
575 for Delivery. *N Engl J Med*. Published online April 13, 2020. doi:10.1056/NEJMc2009316
- 576 67. Guan W, Liang W, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in  
577 China: A Nationwide Analysis. *Eur Respir J*. Published online January 1, 2020.  
578 doi:10.1183/13993003.00547-2020
- 579 68. Chen C, Zhang J, Xia H, et al. Epidemiology of preterm birth in China in 2015 and 2016: a  
580 nationwide survey. *The Lancet*. 2018;392:S73. doi:10.1016/S0140-6736(18)32702-8
- 581 69. Moore SA, Dietl CA, Coleman DM. Extracorporeal life support during pregnancy. *J Thorac  
582 Cardiovasc Surg*. 2016;151(4):1154-1160. doi:10.1016/j.jtcvs.2015.12.027
- 583 70. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following  
584 COVID-19 infection. *Lancet Infect Dis*. Published online 2020. doi:10.1016/S1473-3099(20)30195-X
- 585 71. He J, Liu Z-W, Lu Y-P, et al. A Systematic Review and Meta-Analysis of Influenza A Virus Infection  
586 During Pregnancy Associated with an Increased Risk for Stillbirth and Low Birth Weight. *Kidney  
587 Blood Press Res*. 2017;42(2):232-243. doi:10.1159/000477221
- 588 72. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission  
589 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical  
590 records. *The Lancet*. 2020;395(10226):809-815. doi:10.1016/S0140-6736(20)30360-3
- 591 73. Liu Y, Chen H, Tang K, Guo Y. Clinical manifestations and outcome of SARS-CoV-2 infection during  
592 pregnancy. *J Infect*. doi:10.1016/j.jinf.2020.02.028
- 593 74. Woo PCY, Lau SKP, Wong BHL, et al. Detection of specific antibodies to severe acute respiratory  
594 syndrome (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus  
595 pneumonia. *J Clin Microbiol*. 2004;42(5):2306-2309. doi:10.1128/jcm.42.5.2306-2309.2004

596

597

598

599

600

601

602






Fig 1 PRISMA (preferred reporting items for systematic reviews and meta-analyses) flowchart of included studies

603

604

605

606

607

608

609




Fig 2: Maternal symptoms, co-morbidities and adverse pregnancy outcomes in pregnant women with COVID-19. Data was collated from studies reported in Supplementary Table 1. The actual values are given in supplementary table 2 and 3. n is the number of women from whom the data is derived for each outcome. GDM: Gestational Diabetes Mellitus, DM: Type 1 or 2 Diabetes Mellitus

610

611

612

613

614

615

616

617

618

619

620

621

622

623

	Data available	Nos.	%
Full Term	386	280	74
Preterm <37wks	386	98	26
Respiratory distress syndrome	369	31	8
Pneumonia	369	30	8
Death	369	4	1
Still birth	369	4	1.6
SARS-CoV-2 positive	313	24	8

624

625 **Table 1:** Neonatal outcomes born to COVID-19 mothers. Data available is numbers of neonates  
626 for whom the data was reported by the authors. Nos. is numbers with the outcome and the  
627 percentage (decimal rounded off) are given.

628

629

	Nos	%
Total New-borns	395	
Tested	313	80
Infected	24	7
PCR +ve	17	5
Antibody tested	8	3
Antibody positive	7	88
IgM only	4	50
IgG and IgM	7	88
Clinical Pneumonia	30	8
<b>48h cutoff</b>		
Tested	264	84
Positive	21	8

630

631 **Table 2:** Prevalence and vertical transmission of SARS-CoV-2 from COVID-19 mothers. 48h  
632 cut-off is data is derived out of neonates tested within first 48 hours by lab test (PCR and/or  
633 antibody testing) and the sample tested is known. The percentage are rounded off to the decimal.

634

635

636

637

638

639

640

641

642

643

644

645

646

	Nos of women	%
Studies that reported treatment (n=33)	327	
Antiviral (Interferons, Ganciclovir, Arbidol hydrochloride, Oseltamivir, Lopinavir, Ritonavir, Remdesivir)	160	62.7
Antibiotics (Azithromycin, Cefotiam hydrochloride, moxifloxacin, ceftriaxone)	140	54.9
Chinese herbal medicine (Jinyebaidu and Lianhuaqingwen)	55	21.6
Hydroxychloroquine	59	23.1
Steroids (methylprednisolone)	27	10.6
Mechanical ventilation	31	12.2
Oxygen with nasal cannula	100	39.2

647

**Table 3 :** Treatments given to mothers infected with SARS-CoV-2

648